Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes.
Current Japanese encephalitis vaccines are derived from strains of genotype III, yet heterologous genotypes are emerging in endemic areas. Inactivated vaccines given to European travelers were found to elicit protective levels of neutralizing antibodies against heterologous strains of genotypes I-IV.
Haartman Institute, University of Helsinki, Finland.
Elina O
EO
Erra
Helena Hervius
HH
Askling
Sutee
S
Yoksan
Lars
L
Rombo
Jukka
J
Riutta
Sirkka
S
Vene
Lars
L
Lindquist
Olli
O
Vapalahti
Anu
A
Kantele
D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D003429:Cross Reactions / Q000276:immunology*; D004664:Encephalitis Virus, Japanese / Q000235:genetics* / Q000276:immunology*; D004672:Encephalitis, Japanese / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D005838:Genotype; D006801:Humans; D022321:Japanese Encephalitis Vaccines / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015164:Vaccines, Inactivated / Q000276:immunology; D055815:Young Adult
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines; D015164:Vaccines, Inactivated